Login / Signup

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate.

Katy MasonJoshua BarnettSofia Pappa
Published in: Therapeutic advances in psychopharmacology (2021)
The introduction of ALAI had a substantial impact on long-term clinical outcomes in this naturalistic cohort; more than half of patients continued treatment and had no admission during 2 years of follow up. There were no significant differences in hospitalisation rates between patients on ALAI and PP1M at 2 years.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • randomized controlled trial
  • emergency department
  • systematic review
  • prognostic factors
  • replacement therapy